Related Experiment Videos
The MDR1 3435 polymorphism in patients with rheumatoid arthritis
A Pawlik1, J Wrzesniewska, I Fiedorowicz-Fabrycy
1Department of Pharmacokinetics and Therapeutic Drug Monitoring, Pomeranian Medical University, ul Powstanców Wielkopolskich 72, Poland. pawand@poczta.onet.pl
International Journal of Clinical Pharmacology and Therapeutics
|October 19, 2004
Summary
The MDR1 C3435T polymorphism is not linked to rheumatoid arthritis (RA) susceptibility. However, the 3435TT genotype may improve remission rates for RA patients treated with certain drugs.
Area of Science:
- Genetics
- Immunology
- Pharmacogenomics
Background:
- Rheumatoid arthritis (RA) is a complex autoimmune disease influenced by genetic and environmental factors.
- P-glycoprotein (P-gp), encoded by the MDR1 gene, is a transporter protein involved in drug metabolism and immune processes.
- The MDR1 C3435T polymorphism affects P-gp activity and has been investigated for its role in various diseases.
Purpose of the Study:
- To investigate the association between the MDR1 C3435T polymorphism and rheumatoid arthritis susceptibility.
- To evaluate the correlation of this polymorphism with disease activity and treatment response in RA patients.
Main Methods:
- A case-control study involving 92 RA patients and 97 healthy controls.
- Genotyping of the MDR1 C3435T polymorphism using the PCR-RFLP method.
Main Results:
- No significant difference in MDR1 C3435T genotype distribution was observed between RA patients and controls.
- Patients with the 3435TT genotype showed a 2.89-fold higher probability of RA remission with methotrexate and glucocorticosteroids.
- Individuals with 3435CC and 3435CT genotypes had a 2.89-fold higher risk of active, therapy-resistant RA.
Conclusions:
- The MDR1 C3435T polymorphism is not a significant genetic risk factor for RA susceptibility.
- This polymorphism may influence RA disease activity and patient response to disease-modifying antirheumatic drugs (DMARDs).